Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 SEK | -4.95% | -7.25% | -38.26% |
04-25 | AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-10 | Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR). | CI |
Sales 2024 * | - | Sales 2025 * | 60 5.49 7.5 | Capitalization | 125M 11.48M 15.67M |
---|---|---|---|---|---|
Net income 2024 * | -46M -4.21M -5.75M | Net income 2025 * | -7M -641K -875K | EV / Sales 2024 * | - |
Net cash position 2024 * | 42.5M 3.89M 5.31M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2,090,263 x |
P/E ratio 2024 * |
6.73
x | P/E ratio 2025 * |
-1.84
x | Employees | 11 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 36.1% |
1 day | -4.95% | ||
1 week | -7.25% | ||
Current month | +5.49% | ||
1 month | +12.61% | ||
3 months | -41.28% | ||
6 months | -51.64% | ||
Current year | -38.26% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Jönsson
CEO | Chief Executive Officer | 56 | 20-01-07 |
Johan Sandin
FOU | Founder | 54 | 16-11-21 |
Birgitta Lundvik
DFI | Director of Finance/CFO | 57 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 16-12-31 | |
Ragnar Linder
BRD | Director/Board Member | 71 | 16-12-31 |
Ellen Donnelly
BRD | Director/Board Member | 50 | 17-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 1.92 | -4.95% | 89 919 |
24-04-26 | 2.02 | -1.46% | 191,004 |
24-04-25 | 2.05 | -2.38% | 186,896 |
24-04-24 | 2.1 | +5.79% | 117,624 |
24-04-23 | 1.985 | -4.11% | 55,256 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 11:29 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.26% | 11.44M | |
-2.72% | 103B | |
+1.67% | 95.28B | |
+1.46% | 22.15B | |
-15.70% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.28% | 16.05B | |
+4.57% | 13.68B | |
+34.96% | 12.17B |
- Stock Market
- Equities
- ALZCUR Stock